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Abstract
Authors have continued clinical research of Calorie Restriction (CR) and Low Carbohydrate Diet (LCD) and
present a case with precise observation of continuous glucose monitoring (CGM). The patient is 38 years-old
females with type 2 diabetes mellitus (T2DM), who showed BMI 19.6, postprandial blood glucose 277 mg/dL. HbA1c
12.6%, glycoalbumin 31.8% (11.6-16.4), HOMA-R 2.8, HOMA-β 8.5, urinary excretion of C-peptide 67 μg/day, and
normal range of liver, renal, lipid exams. She was given three stage intervention. The protocol was
• Day 1-2; CR meal with 60% carbohydrate,
• Day 3-5; LCD meal with 12% carbohydrate,
• Day 6-13; LCD+Sodium–glucose cotransporter 2(SGLT2) inhibitors (Suglat 50 mg, Ipragliflozin L-Proline).
The glucose variability was monitored using FreeStyle Libre Pro (Abbott) for 14 days. Blood glucose was
decreased as
• More than 350 mg/dL,
• 180-200 mg/dL,
• 100-150 mg/dL in day 7-9, and 90-120 mg/dL in day 10-13.
Acute decrease of blood glucose was found 3 hours after giving Suglat, which was remarkable finding. These
results suggest the improving glucose variability of LCD in short term, the acute and strong efficacy of SGLT2
inhibitors for glucose metabolism, and clinical usefulness of simultaneous observation of glucose fluctuation.
Keywords: Sodium–glucose cotransporter 2 inhibitors; Continuous
glucose monitoring; Freestyle libre pro; Ipragliflozin L-proline;
Glucose variability; Low carbohydrate diet
Abbreviations: LCD: Low Carbohydrate Diet; T2DM: Type 2
Diabetes Mellitus; CR: Calorie Restriction; HOMA-R: Homeostasis
Model Assessment of Insulin Resistance; HOMA-β: Homeostasis
Model Assessment of β cell function; NCD: Non-Communicable
Diseases; ACP: American College of Physicians; ADA: American
Diabetes Association; DIRECT: Dietary Intervention Randomized
Controlled Trial; JLCDPA: Japan LCD Promotion Association; MTT:
Meal Tolerance Test; FGM: Flash Glucose Monitoring; CGM:
Continuous Glucose Monitoring; IGI: Insulinogenic Index; SGLT2:
Sodium–Glucose Cotransporter 2; 75gOGTT: 75 g Oral Glucose
Tolerance Test; IRI: Immunoreactive Insulin; RCTs: Randomized
Controlled Trials; BMI: Body Mass Index.
Introduction
Historically speaking, various health problems and diseases were
threats to humans in each era. In the past, infectious diseases such as
tuberculosis had been raging, but at present non-communicable
diseases (NCD) has been important. Among them, diabetes mellitus
and metabolic syndrome have become major problems medically and
economically [1]. This influence is spreading to the world in the
developed countries, as well as developing countries [2]. The principle
for the therapy is an appropriate diet, and medicine can be given if
necessary. As to the adequate diagnosis and treatment of diabetes,
several medical academies have been on discussion [3]. Recent
controversies are found for recommended HbA1c value in some
societies, such as American College of Physicians (ACP), and
American Diabetes Association (ADA) [4,5].
Under such circumstances, calorie restriction (CR) was previously
broadly prevalent for standard diet therapy for long. After that, Atkins
and others advocated the trial of Low Carbohydrate Diet (LCD), which
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was spreading in the European and North American countries [6].
Furthermore, lots of evidence for LCD has been accumulated until
now and the efficacy of LCD has been reported. In particular, Dietary
Intervention Randomized Controlled Trial (DIRECT) Group clarified
the clinical effects of LCD until 2 years and also until 4 years [7,8].
After that, there are several reports indicating the clinical usefulness of
LCD [9,10].
On the other hand, the authors firstly introduced LCD and started
in Japan [11]. After that, we have continued published many books and
developed educational seminars in order to inform people of correct
information of LCD and nutritional therapy. In addition, we
established Japan LCD Promotion Association (JLCDPA) for the
purpose of proceeds the movement from social point of view. Through
these activities, we have expanded various activities concerning LCD
for the patients, healthcare professionals and general people.
For our research development related to LCD, we are continuing
various aspects of investigation. They include
• The popularization of three types of LCDs that can be applied on a
daily basis, which are petit LCD, standard LCD and super LCD
[12],
• The concentration of blood ketone bodies increased in response to
LCD continuation, as well as physiological hyperketonemia in the
axis of fetus, placenta, newborn and mother [13],
• Glucose variability and daily profile of blood glucose on CR and
LCD [14],
• Meal tolerance test (MTT) using CR breakfast with carbohydrate
70 g [15].
In recent years, the development of medical technology for blood
glucose measurement has been found. Then, investigation of blood
glucose variability has become possible with detail observation. As a
matter of fact, flash glucose monitoring (FGM) and continuous glucose
monitoring (CGM) systems have been introduced in the medical
practice. Consequently, the analysis of detail glucose fluctuation can be
measured easier than before. We have had lots of diabetic cases with
the study of CGM. Among them, we have recently experienced an
interesting case with type 2 diabetes (T2DM). When she was switched
from CR to LCD, blood glucose variability rapidly improved
remarkably in the short term. Furthermore, providing SGLT2 inhibitor
cause blood glucose decreasing in a few hours. We analyzed this case in
detail, and report in this article.
Case Presentation
Patient and history
The patient is 38 years-old female with T2DM. History of present
illness revealed that she was diagnosed as T2DM at the age of 26. After
that, she had been treated by anti-diabetic oral agents. However, her
diabetic control has not been satisfactory for long. Then, she was
introduced and transferred to our diabetic clinic for further evaluation
and treatment.
Physicals and routine exams
On first contact, her physical was normal, such as vitals, heart, lung,
abdomen and neurological findings. She was 164 cm in height and 52.7
kg in weight, with 19.6 kg/m2 of body mass index (BMI).
Laboratory examination on routine revealed as follows
Postprandial blood glucose 277 mg/dL. HbA1c 12.6%, glycoalbumin
31.8% (11.6-16.4). Three weeks later, she was admitted for detail
evaluation and practical and actual therapy for current diabetic
condition. At this point, HbA1c was 11.2%, and glycoalbumin was
26.4%.
General examination
Urinalysis showed that pH 6.0, protein negative, sugar 1892 mg/dL,
urinary microalbumin 6.5 mg/g･cre (<30). Occult blood in stool was
negative. ECG was within normal limit. Echograms of carotid artery,
heart and abdomen were unremarkable.
Blood biochemistry
The results of blood test were as follows. CBC (complete blood 
count): WBC 4100/μl, RBC 492 × 104/μl, Hb 13.1 g/dL, Ht 39.9%, CRP 
0.03 mg/dL, Na 138 mEq/L, K 4.6 mEq/L, Cl 101 mEq/L, BUN 13 mg/
dL, Cre 0.51 mg/dL, Uric Acid 4.1 mg/dL, Ca 9.5 mg/dL, P 3.4 mg/dL, 
Total protein 7.1 g/dL, Albumin 4.2 g/dL, AlP 242 IU/mL, GOT 16 
IU/mL, GPT 16 IU/mL, LDH 162 IU/mL, r-GTP 15 IU/mL, ChE 324 
U/L (200-459), Amylase 74 U/L (37-125), Triglyceride 53 mg/dL, 
HDL-C 81 mg/dL, LDL-C 138 mg/dL, Cystatine C 0.60 mg/L 
(0.56-0.87).
Diabetes-related exam
On the morning of day 2, fasting blood glucose and IRI was 254
mg/dL and 4.5 μU/mL. Homeostasis model assessment of insulin
resistance (HOMA-R) was 2.8 and homeostasis model assessment of β
cell function (HOMA-β) was 8.5. In addition, glucose and IRI on 30
minutes after CR breakfast was 317 mg/dL and 14.0 IU/mL,
respectively. The carbohydrate content in the breakfast is 70 g, in which
1400 kcal per day and 60% of carbohydrate for 3 meals. Insulinogenic
index (IGI) for 70 g of carbohydrate per os is calculated as (14.0-4.5)/
(317–254)=0.15. Urinary excretion of C-peptide on day 2 and day 4
was 67.0 μg/day and 55.2 μg/day, respectively.
Methods and Clinical Progress
Protocol of three intervention
This study includes the following three steps:
• CR was provided in day 1 and 2. The detail of CR is 1400 kcal/day
with 60% of carbohydrate.
• LCD was provided from day 3 to 5. The detail of LCD is 1400
kcal/day with 12% of carbohydrate, which is called super-LCD in
our research protocol.
• Oral medicine was added on day 6 to 13. Anti-diabetic agent of
Sodium–glucose cotransporter 2 (SGLT2) inhibitors (Suglat 50 mg,
Ipragliflozin L-Proline) was started on the morning of day 6. The
meal is as same as LCD and continued from day 6 to 13.
Method of CGM study
Daily profile of blood glucose was measured by FreeStyle Libre Pro.
As to products, there are two types of Freestyle Libre [16]. One is
Personal CGM, FreeStyle Libre, and another is Professional CGM,
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FreeStyle Libre Pro. The latter apparatus was used in this study, which
is produced by Abbott Diabetes Care Inc. [17,18].
Result of CGM
The results for 13 days are shown in Figure 1. The meal time is
regular and stable at 0800h, 1200h and 1800h, 3 times per day. After
three meals, blood glucose levels were increased in postprandial
periods.
For day 1-2 with 60% of carbohydrate on CR meal, daily blood
glucose persisted high level. The portion of glucose 350 mg/dL means
actually more than 350 mg/dL, because of upper limit of the system is
350 mg/dL and less than 350 mg/dL.
Figure 1: CGM data for 3 intervention study in patient with T2DM. CR meal in day 1-2. LCD meal in day 3-5. LCD + SGLT2 inhibitor day 6-9.
Red arrows indicate 3 meals per day. Asterisk (*) shows the point of clinical effect of SGLT2 inhibitor on day 6.
During day 3-5, blood glucose was decreased rather acutely than
day 1-2. The decrease degree would be about 150 mg/dL, and the
average blood glucose on day 3-5 was approximately 180 mg/dL to 200
mg/dL. When blood variability was compared between day 3 and day
5, the latter showed more decreased blood glucose level than the
former. On the afternoon of day 5, blood glucose was decreased to the
level less than 180 mg/dL.
On the morning at 0800h of day 6, anti-diabetic agent of SGLT2
inhibitors (Suglat 50 mg, Ipragliflozin L-Proline) was started. It was
continued from day 6 to day 13. Three hours after the initiation of
SGLT2 inhibitor, blood glucose has abruptly decreased to around 120
mg/dL to 150 mg/dL and persisted after that. On day 7-9, blood
glucose maintained about 100 mg/dL to 150 mg/dL. On day 10-13,
glucose maintained from 90 mg/dl to 120 mg/dL in the daytime, and
70 mg/dL to 90 mg/dL in the night, in particular rather lower from
0100h to 0600h.
Discussion and Conclusion
In this report, a patient with T2DM received three stages of
treatment. These are i) CR meal, ii) LCD meal, and iii) LCD+SGLT 2
inhibitor, and blood glucose variability was investigated using recently
developed FreeStyle Libre Pro (Abbott). As a result, hyperglycemia
continued on day 1
-2 on CR. After that, blood glucose level dropped daily at day 3-6,
indicating the short-term effect of LCD. Furthermore, by the
administration of SGLT 2 inhibitor agent, blood glucose was
dramatically decreased, suggesting a rapid and high efficacy of the
agent.
From the clinical application of FreeStyle Libre Pro, it seems to be
simple, useful and informative. There are not particular problems of
measurement data or equipment worn on arms, and so on [16].
As a matter of fact, the discrepancy of the data would be examined.
In other words, there was a data divergence between HbA1c measured
at hospitalization and HbA1c anticipated by FreeStyle Libre Pro from
blood glucose data. The reason for this would be partly attributed to
the fact that CGM cannot detect occasional acute and spike increase of
the blood glucose [19]. One of the reasons would be blood
measurement is done in every 15 minutes as reported in the past [20].
Similar situation was observed in our previous report. From now on,
accumulation of data will be expected to solve this problem.
This case showed the HOMA-R value elevated to 2.8. In general, it is
judged that HOMA-R shows normal under 1.6, and insulin resistance
more than 2.5. Then, this case has obvious insulin resistance for long
history of diabetes [21].
Further, HOMA-β was 8.5. As to the interpretation for the value
HOMA-β, 40-100% is normal, 30% or less is a mild secretory capacity
reduction, 15% or less means a clearly reduced insulin secretion ability,
and 3% or less means that the insulin ability is regarded as the level of
exhaustion. Consequently, the case was evaluated to be obvious
secretion reduction [22].
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As mentioned above for this case, continuation of hyperglycemia for
many years probably induced the existence of a vicious circle due to
sugar toxicity. Therefore, it seems that both insulin resistance and
insulin secretion ability where was also decreased to the moderate
degree. However, a short period of providing LCD meal has reduced
the sugar toxicity and therefore the clinical significance of LCD would
be effective and meaningful.
A method for evaluating insulin secretion from the pancreas has
been known so far. It is IGI for the examination of 75 g oral glucose
tolerance test (75gOGTT), which can be calculated with glucose and
immunoreactive insulin (IRI) at 0 and 30 minutes.
Similarly, the authors have been studying the responses of blood
glucose and IRI in response to LCD and/or CR meals so far. Among
them, MTT trials using CR breakfast has been reported [15]. CR
breakfast includes 70 g of carbohydrate, and IGI was examined like
75gOGTT. As a result, it seems that IGI-carbo 70 is actually useful in
the clinical diabetic practice and research [15].
In current case, the blood glucose increased from 254 mg/dL to 317
mg / dL after 30 minutes due to ingestion of 70 g carbohydrate, and the
ratio of IGI-Carbo 70 was calculated to be 0.15. Compared with the
conventional IGI-75 g-glucose, the insulin secretion ability was
clinically shown to be decreased.
In recent years, SGLT2 inhibitors have been used. They are one of
the new oral anti-hyperglycemic agents, which seem to show
remarkable effect for glucose variability [23,24]. Their mechanism
includes the inhibition of renal reabsorption of glucose and promotion
of glycosuria, which can lead to a reduction of blood glucose
independent from insulin activity [24,25].
The administration of ipragliflozin once per day has safe and
effective decrease of HbA1c, fasting blood glucose and body weight in
randomized controlled trials (RCTs) [26]. Its beneficial effects were
also recognized in post-marketing surveillance study [27].
In this case, the effect of SGLT 2 inhibitor was remarkably observed.
The agent was administered at 0800 h on day 6. After that, blood
glucose has dropped sharply from 1100h. It is involved in the
mechanism of action of SGLT2 inhibitor [28]. This is probably from
the reduced situation of "glucose toxicity" which were persisted by
long-term hyperglycemia. Glucose toxicity has been known where
chronic hyperglycemia directly impairs both insulin secretion and
sensitivity [29]. SGLT2 inhibitors have an insulin-independent
mechanism of action, which involves increasing urinary glucose
excretion and decreasing blood glucose [29].
Pharmacological research data of ipragliflozin showed Cmax 1045
ng/mL, Tmax 1.43 hrs, and t 1/2, 14.9 hrs. Clinical effects are seen
about 3 hours, and administration once a day is usual [28,30].
Other data showed that glucose excretion in urine is 71 g/day in
average for normal subjects, 61 g/day for mild renal disorder, 38 g/day
for moderate renal disorder, and 12 g/day for severe renal disorder. In
other words, it can be interpreted that it is close to continuing the
carbohydrate limit of 70 g per day. When limiting carbohydrate intake
by dietary restriction and discharging 70 g of sugar per day with SGLT
2 inhibitor, both has common situation in sugar metabolism with
doubling clinical effects [28,30].
As for ipragliflozin, usual dosage for adult is 50 mg orally
administered once daily before or after breakfast. This dose can be
increased up to 100 mg with careful monitoring of the clinical progress
of the patient if needed [31]. The inhibitory effects of ipragliflozin on
SGLT2 and SGLT1 were studied in human SGLT2- or SGLT1-
expressing CHO cells. As a result, IC50 values were 7.38 and 1880
nmol/L, respectively [31]. SGLT2 inhibitors have maintaining activity
for 48 h, and then we can arrange to give the patient as-required single
doses instead of daily administration [32]. It can be helpful for the
therapy of T2DM to reduce the adverse effects such as urinary tract
infection, genital infection, hypoglycemia and so on [33].
In summary, we examined the detailed blood glucose fluctuation by
CGM in a patient with T2DM, associated with 3 interventions of CR
meal, LCD meal, LCD+SGLT 2 inhibitor. Blood glucose variability was
improved with LCD meal for 1-2 days, and was dramatically improved
3 hours after the administration of SGLT 2 inhibitor. Thus,
hyperglycemia and glucose toxicity seemed to be reduced in short
period. These data would become basic and reference data and be
useful for future CR and LCD diet therapy and actual administration
of SGLT2 inhibitor.
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